A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer

Crawford, E. David

doi:10.1016/s0090-4295(99)80368-9

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…erefore, the present study aimed to compare the effects of different treatment methods on the overall survival (OS) and failure-free survival (FFS) of patients with mHSPC through direct meta-analysis and network meta-analysis based on previous relevant meta-analyses [12][13][14] and various randomized controlled trials (RCTs [15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32]).…”

Section: Objectivementioning

confidence: 99%

Systemic Therapy for Metastatic Hormone-Sensitive Prostate Cancer: A Randomized Controlled Trial-Based Network Meta-Analysis

Kang

et al. 2022

Journal of Oncology

View full text Add to dashboard Cite

Objective. To compare the effects of different treatment strategies for metastatic hormone-sensitive prostate cancer (mHSPC) using a network meta-analysis. Methods. English databases (PubMed, Embase, and medRxiv) and Chinese databases (Wanfang and CNKI) were searched for randomized controlled trials (RCTs) on the treatment of mHSPC from inception to June 1, 2021. The overall survival (OS) and failure-free survival (FFS) reported by the included studies were extracted from each study for network meta-analysis. Moreover, the priority ranks of the treatment methods were determined. Results. A total of 18 RCTs with 14,682 patients were included in this study. Androgen-deprivation therapy (ADT) + apalutamide (APA) showed the highest probability of improving the OS (96.2%) and FFS (68.0%). In addition, the patients were stratified into ten subgroups as follows: low/high tumor burden (CHAARTED criteria); Gleason score ≤7/≥8; Eastern Cooperative Oncology Group (ECOG) = 0/≥1; with/without prechemotherapy; and cooperative with/without concomitant radiotherapy. For the improvement of OS, the leading treatments were as follows: (1) ADT + enzalutamide (ENZA) (64.1%)/ADT + abiraterone acetate + prednisone (AAP) (54.3%); (2) ADT + ENZA (41.9%)/ADT + APA (39.2%); (3) ADT + ENZA (39.2%)/ADT + APA (32.1%); (4) ADT + radiotherapy (51%)/ADT + ENZA (76.7%); (5) ADT + AAP (51%)/ADT + AAP (60%). Conclusion. Three endocrine therapy drugs, abiraterone, enzalutamide, and APA, exhibited the best effects in improving the OS and FFS in all patients and subgroups; however, APA had the most prominent treatment effects. Therefore, ADT + APA should be applied as the common treatment for patients with HSPC based on objective and clinical conditions. Trial Registration. This meta-analysis has been registered on the PROSPERO website (Trial number: https://www.crd.york.ac.uk/prospero/CRD42020221062).

show abstract